Plans to expand African vaccine production encounter challenges as Moderna's pause in Kenya underscores the obstacles in developing a competitive vaccine sector. The new WHO treaty and IHR amendments shift focus, sparking African opposition. China's vaccine developers shift to new targets due to unused mRNA COVID shots, facing revenue constraints. African governments' push for self-production of medicines and vaccines post-pandemic signals positive change.
African governments’ newfound determination to produce their own medicines and vaccines shows that even catastrophic events like a pandemic can lead to positive, unforeseen outcomes, writes @UMassAmherst’s @Jayati1609. https://t.co/FsxRsQ2WVK
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue https://t.co/IS35K9TXNI
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. More here: https://t.co/VJAZkAuR4i
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. https://t.co/awKbTcgD2p https://t.co/awKbTcgD2p
The new WHO treaty & IHR amendments will divert funds away from preventing and treating deadly diseases like malaria and TB so that scientists can find more viruses in bat caves. Great article by Anjuli Webster on African opposition to the WHO treaty. https://t.co/oTriTmHecD https://t.co/YkCRlTDNT7
Moderna’s pause on their Kenya project highlights difficulties in creating a competitive vaccine sector in Africa. https://t.co/R0Os7JKJss
Plans to expand African vaccine production face steep hurdles | Science | AAAS https://t.co/bsaYSlXkhM